SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

Concord Drugs

BSE: 538965 29 Sep 2025
Healthcare
₹ 69
Concord Drugs Limited specializes in Pharmaceuticals within the Healthcare sector.

Concord Drugs - Share Price & Details

Market Cap
₹66.2
High /Low
71.0 / 26.1
Stock P/E
154.0
Book Value
₹34.1
Dividend Yield
0.0
ROCE
5.2
ROE
₹1.0
Face Value
10.0
PEG Ratio
-3.83
EVEBITDA
₹19.6
Debt
19.2
CMP / FCF
101.0
Debt to equity
₹0.56
NP Ann
0.34
High price all time
91.2
Piotroski score
₹6.0
Graham Number
18.2
No. Eq. Shares
1.0
Net CF
₹-0.02
Net profit
0.43
Price to book value
1.94
Interest Coverage
₹1.4
Low price all time
11.7
Industry PE
33.0
Reserves
₹24.1
Free Cash Flow
₹1.39

Broker Recommendations

No broker recommendations available

We couldn’t find any recent recommendations for this company (matched by symbol or BSE code). Please check back later.


Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
FABINO ENTERPRISES LIMITEDNANANANA5.0984.8
Triochem Products Ltd.,NANANANA0
Concord Drugs LimitedNANANANA66.2154.0
GODAVARI DRUGS LTD.NANANANA65.217.2
Jeevan Scientific Technology LNANANANA63.41,268

Peer Comparison Chart


About Concord Drugs

Concord Drugs Limited, with Security Code 538965, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Order Book


Latest News

Concord Drugs Achieves 52-Week High Amid Strong Market Sentiment and Outperformance

(15 Sep 2025)
Concord Drugs has achieved a new 52-week high of Rs. 71, following an impressive 13.6% gain over the past eight days.
Read more →

Concord Drugs Achieves 52-Week High Amid Strong Small-Cap Market Performance

(11 Sep 2025)
Concord Drugs has reached a new 52-week high of Rs. 70.03, reflecting a strong performance in the Pharmaceuticals & Biotechnology sector.
Read more →

Concord Drugs Achieves 52-Week High Amid Strong Market Performance Trends

(10 Sep 2025)
Concord Drugs has achieved a new 52-week high of Rs. 68.66, reflecting strong performance in the Pharmaceuticals & Biotechnology sector.
Read more →

Concord Drugs Adjusts Evaluation Score Amid Mixed Technical Indicators and Performance Challenges

(28 Aug 2025)
Concord Drugs, a microcap in the Pharmaceuticals & Biotechnology sector, has recently adjusted its evaluation score, reflecting a shift in...
Read more →

Akums Drugs & Pharmaceuticals consolidated net profit rises 5.50% in the June 2025 quarter

(24 Aug 2025)
Net profit of Akums Drugs & Pharmaceuticals rose 5.50% to Rs 63.48 crore in the quarter ended June 2025 as against Rs 60.17 crore during the...
Read more →

Concord Drugs Standalone June 2025 Net Sales at Rs 13.38 crore, up 110.66% Y-o-Y

(23 Aug 2025)
Quarterly Net Profit at Rs. 0.11 crore in June 2025 up 852.95% from Rs. 0.01 crore in June 2024. EBITDA stands at Rs. 0.94 crore in June...
Read more →